Eagle Pharmaceuticals IncOver The Counter Market:EGRX
- LAST PRICE0.8600
- TODAY'S CHANGE (%)0.0295 (3.5521%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.8300 / 0.8305
- Day Range
- 52 Week Range
- Volume1,416
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | EGRX |
|---|---|---|
| 09:32 ET | 100 | 0.83 |
| 09:35 ET | 100 | 0.8301 |
| 09:53 ET | 187 | 0.8302 |
| 09:55 ET | 100 | 0.8401 |
| 10:38 ET | 181 | 0.86 |
| 12:19 ET | 500 | 0.86 |
Nov 15, 2024
Eagle Announces Update on Delisting from Nasdaq and SEC Deregistration, from 5:00PM ET on Friday Nov 15, 2024 by Dow Jones
5:00PM ET on Friday Nov 15, 2024 by Dow Jones
Nov 12, 2024
Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial Officer, from 7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
Oct 31, 2024
Eagle Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan, from 8:00AM ET on Thursday Oct 31, 2024 by Dow Jones
8:00AM ET on Thursday Oct 31, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Eagle Pharmaceuticals Inc | 12.3M | 0.9x | -4.75% |
Shengtai Pharmaceutical Inc | 10.0 | 0.0x | --- |
Medicine Man Technologies Inc | 6.2M | --- | --- |
Lotus Pharmaceuticals Inc | 2.2M | 0.0x | +42.39% |
Cumberland Pharmaceuticals Inc | 14.9M | -1.5x | --- |
Aoxing Pharmaceutical Company Inc | 4.9M | -0.4x | --- |
Company Information
Eagle Pharmaceuticals, Inc. is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial capabilities. The Company is focused on developing medicines that result in improvements in patients' lives. The Company's commercialized products include vasopressin, PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO and BARHEMSYS through its wholly owned subsidiary Acacia Pharma Inc. Its oncology and central nervous system (CNS)/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. The Company also has a research and development facility in Cambridge, Massachusetts. The Company has office space in Palm Beach Gardens, Florida and Indianapolis, Indiana. The Company’s subsidiaries include Eagle Biologics, Inc., Eagle Research Lab Limited, Acacia Pharma Group plc, Acacia Pharma Limited and Acacia Pharma Inc.
Contact Information
- Headquarters
- 50 Tice Boulevard, Suite 315WOODCLIFF LAKE, NJ, United States 07677
- Phone
- 201-326-5300
- Fax
- 302-655-5049
Executives
- Interim Executive Chairman of the Board, Interim Principal Executive Officer
- Michael Graves
- Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
- Christopher Krawtschuk
- Director
- Steven Ratoff
- Independent Director
- Luciana Borio
- Independent Director
- Richard Edlin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $12.3M |
|---|---|
Revenue (TTM) | $257.6M |
Shares Outstanding | 13.0M |
Eagle Pharmaceuticals Inc does not pay a dividend. | |
Beta | 0.71 |
EPS | $0.91 |
Book Value | $17.94 |
P/E Ratio | 0.9x |
Price/Sales (TTM) | 0.0 |
Price/Cash Flow (TTM) | 0.4x |
Operating Margin | 13.98% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
